Monday, April 15, 2024
BC Platforms (BCP) and NTT Life Science Corporation have teamed up in an exclusive partnership to advance data-driven medicine, particularly in Japan. The collaboration, which was officially inaugurated at a joint facility opening ceremony in Tokyo, aims to spearhead the Japan Precision Medicine PlatformTM (JPP), facilitating the secure and efficient use of clinical data across the nation.
This partnership, announced in October 2023, grants BCP and NTT exclusive rights within the Japanese market under the JPP umbrella. Through a multiyear effort, the platform will integrate, curate, and harmonize healthcare data, fostering collaboration among researchers to accelerate the development of new therapies.
Laurent Samama, Chairman of the Board at BCP, expressed enthusiasm for the partnership, emphasizing its role in scaling up their capabilities and maximizing their value proposition. The collaboration targets a positive impact on patient care through personalized medicine, utilizing real-world data to identify suitable candidates for clinical trials.
NTT's strategic goal of creating value through data-driven technology aligns with this partnership, as outlined in their medium-term management strategy. Akiko Kudo of NTT emphasized the importance of quickly establishing a market presence alongside BCP, a globally recognized player in the medical field.
Kouji Korekawa, President and CEO of NTT Life Science, highlighted their commitment to revolutionizing healthcare solutions, drawing upon their extensive experience in medical research. Leveraging their existing network and expertise, they aim to drive adoption of the JPP across Japan.
Nino da Silva, Managing Director APAC at BC Platforms, underscored the combined strength of NTT's infrastructure and BCP's technology in building a robust medical data ecosystem. The collaboration aims to provide unparalleled access to real-world data for global pharmaceutical companies and research organizations.
Source: bcplatforms.com
